A comparative study of pathogen inactivation technologies in human platelet lysate and its optimal efficiency in human placenta-derived stem cells culture

被引:1
作者
Razani, Elham [1 ]
Aghayan, Hamid Reza [2 ]
Alavi-Moghadam, Sepideh [2 ]
Yari, Fatemeh [1 ]
Gharehbaghian, Ahmad [3 ]
Sharifi, Zohreh [1 ]
机构
[1] High Inst Res & Educ Transfus Med, Blood Transfus Res Ctr, Tehran, Iran
[2] Univ Tehran Med Sci, Cell Therapy & Regenerat Med Res Ctr, Endocrinol & Metab Mol Cellular Sci Inst, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Sch Allied Med Sci, Dept Hematol & Blood Banking, Tehran, Iran
关键词
Cell therapy; Gamma irradiation; Mesenchymal stem cells; Pathogen inactivation; Platelet lysate; Ultraviolet; MESENCHYMAL STROMAL CELLS; FETAL BOVINE SERUM; RIBOFLAVIN; PLASMA; REDUCTION; DIFFERENTIATION; EXPANSION; VIRUSES; IMMUNOMODULATION; BACTERIA;
D O I
10.1016/j.jviromet.2022.114478
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Pathogen inactivation (PI) is necessary for the pooled components derived from a biological source. Recently, the use of human platelet lysate (hPL) has increased in the cell manufacturing process as a xeno-free substitute for Fetal Bovine Serum (FBS). Therefore, an effective PI process to produce a pathogen-free hPL with the optimal efficiency in the manufacturing of cell therapy products is a vital requirement. Study design and methods: To evaluate the efficacy of gamma irradiation and riboflavin/ultraviolet light (RB/UV) as PI methods for hPL, the reduction factor (RF) of titer of model viruses and bacteria were examined. Furthermore, the effect of different PI methods on the hPL performance was evaluated by the in vitro expansion of human placenta-derived mesenchymal stem cells (PLMSCs). To compare different study groups, the growth kinetic, immunophenotype, colony formation, and differentiation capacity (osteogenic and adipogenic) of PLMSCs were examined. In addition, the concentration of growth factors was assayed in each study group. Results: Achievement to the RF more than 5 log(10) for all pathogens, showed the effectiveness of two PI methods. In comparison with the other study groups, the dose of 45 kGy gamma irradiation considerably decreased the growth factor level of the hPL. It also showed a significant adverse effect on PLMSCs growth kinetics. The dose of 30 KGy gamma irradiation and RB/UV demonstrated a favorable effect on different assays of the in vitro expanded PLMSCs. Conclusion: The 30 KGy gamma irradiation and RB/UV were effective in the RF of the viral and bacterial models of the contaminated hPL. The efficacy of these PI-hPLs for PLMSCs expansion was preserved. To increase the safety of cell therapy products, PI methods should be considered for the hPL preparations.
引用
收藏
页数:8
相关论文
共 42 条
[1]  
Aghayan H.R., 2020, STEM CELLS GOOD MANU, P213
[2]   Protecting the blood supply from emerging pathogens: The role of pathogen inactivation [J].
Allain, JP ;
Bianco, C ;
Blajchman, MA ;
Brecher, ME ;
Busch, M ;
Leiby, D ;
Lin, L ;
Stramer, S .
TRANSFUSION MEDICINE REVIEWS, 2005, 19 (02) :110-126
[3]   A double-virally-inactivated (Intercept-solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells [J].
Barro, Lassina ;
Su, Yu-Ting ;
Nebie, Ouada ;
Wu, Yu-Wen ;
Huang, Yen-Hua ;
Koh, Mickey B. C. ;
Knutson, Folke ;
Burnouf, Thierry .
TRANSFUSION, 2019, 59 (06) :2061-2073
[4]   Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: Further insights in the search for a fetal calf serum substitute [J].
Bernardo, M. E. ;
Avanzini, M. A. ;
Perotti, C. ;
Cometa, A. M. ;
Moretta, A. ;
Lenta, E. ;
Del Fante, C. ;
Novara, F. ;
De Silvestri, A. ;
Amendola, G. ;
Zuffardi, O. ;
Maccario, R. ;
Locatelli, F. .
JOURNAL OF CELLULAR PHYSIOLOGY, 2007, 211 (01) :121-130
[5]   Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow [J].
Bieback, Karen ;
Hecker, Andrea ;
Kocaoemer, Asli ;
Lannert, Heinrich ;
Schallmoser, Katharina ;
Strunk, Dirk ;
Klueter, Harald .
STEM CELLS, 2009, 27 (09) :2331-2341
[6]   Current strategies to prevent transmission of prions by human plasma derivatives [J].
Burnouf, T. ;
Padilla, A. .
TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2006, 13 (05) :320-328
[7]   Reducing the risk of infection from plasma products: specific preventative strategies [J].
Burnouf, T ;
Radosevich, M .
BLOOD REVIEWS, 2000, 14 (02) :94-110
[8]   Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? [J].
Burnouf, Thierry ;
Strunk, Dirk ;
Koh, Mickey B. C. ;
Schallmoser, Katharina .
BIOMATERIALS, 2016, 76 :371-387
[9]   Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions [J].
Castiglia, Sara ;
Mareschi, Katia ;
Labanca, Luciana ;
Lucania, Graziella ;
Leone, Marco ;
Sanavio, Fiorella ;
Castello, Laura ;
Rustichelli, Deborah ;
Signorino, Elena ;
Gunetti, Monica ;
Bergallo, Massimiliano ;
Bordiga, Anna Maria ;
Ferrero, Ivana ;
Fagioli, Franca .
CYTOTHERAPY, 2014, 16 (06) :750-763
[10]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317